Development of non-iodinated, non ionic, water-soluble metal based compounds for clinical administration as radiographic contrast media.

点击翻译按钮获取中文摘要

Every year Australia spends more than $50 million on importing radiographic contrast media, in an international market worth more than $1 billion pa. Existing iodine based agents, which currently cause major adverse reactions in 1% of the population, could be replaced by new metal based imaging media which provide both enhanced contrast and greater patient safety and comfort. Even a small fraction of the international market would generate millions of dollars in overseas income from a range of potential sources, including licensing/royalties to export by a local start-up company, and expansion of rare earth mining in Australia.